Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients.European journal of haematology · 2025Article
- Transplantation and Cellular Therapy for Older Adults-The MSK Approach.Current hematologic malignancy reports · 2024Review
- Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma.Frontiers in oncology · 2024Review
- Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.Leukemia & lymphoma · 2023Article
- Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation.Blood advances · 2023Article
- What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?Hematology. American Society of Hematology. Education Program · 2022Article
- Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review.Biomedicines · 2022Review
- Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2022Article
- Dose-adjusted high-dose chemotherapy with autologous stem cell transplantation for elderly (≥ 70 years old) lymphoma patients.Annals of hematology · 2022Article
- Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation.Annals of transplantation · 2021Article
- Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma.Blood advances · 2021Article
- Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival.Blood advances · 2021Article
- Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.Bone marrow transplantation · 2021Article
- How we treat mature B-cell neoplasms (indolent B-cell lymphomas).Journal of hematology & oncology · 2021Review
- Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.Current opinion in hematology · 2019Review
- Autologous hematopoietic stem-cell transplant in small-sized and peripheral centers: a 10-year experiment.Therapeutic advances in hematology · 2019Article
- [Efficiency and safety of autologous hematopoietic stem cell transplantation for 19 cases with elderly lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns.Drugs & aging · 2018Review
- Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.The oncologist · 2018Article
- Current trials for frontline therapy of mantle cell lymphoma.Journal of hematology & oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term remission or cure in patients with non-Hodgkin lymphoma (NHL). Limited experience is available on the safety and efficacy of HDT-ASCT in elderly patients. This is a single-center, retrospective study examining outcomes of HDT-ASCT for 202 NHL patients, ages 60 years and older, between January 2001 and December 2012. Overall survival (OS) and progression-free survival (PFS) were analyzed according to age at HDT-ASCT, hematopoietic cell transplantation comorbidity index (HCT-CI), NHL histology, and remission status at the time of HDT-ASCT. The median age was 65 years (range, 60 to 74) and the majority had either diffuse large B cell lymphoma (n = 73, 37%) or mantle cell lymphoma (n = 69, 34%). One hundred and fifteen patients (57%) had high HCT-CI scores at the time of HDT-ASCT. With a median follow-up of 3.6 years (range, 4 to 11.9 years) for survivors, PFS and OS at 3 years were 60% (95% confidence interval [CI], 53% to 68%) and 73% (95% CI, 67% to 80%), respectively. Transplantation-related mortality (TRM) was 4% both at 100 days and at 1 year after HDT-ASCT. Age and HCT-CI score were not associated with OS or PFS, and high HCT-CI did not correlate with TRM. Seven patients (4%) developed secondary myelodysplastic syndrome or acute myeloid leukemia at a median of 35 months (range, 6 to 48) after HDT-ASCT. In this single-center cohort of elderly patients with NHL undergoing HDT-ASCT, this intervention was proven tolerable and effective, with results similar to those of historic controls in younger patients. Our data suggest that age alone should not preclude HDT-ASCT in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.